AR055939A1 - Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso - Google Patents

Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso

Info

Publication number
AR055939A1
AR055939A1 ARP060101835A ARP060101835A AR055939A1 AR 055939 A1 AR055939 A1 AR 055939A1 AR P060101835 A ARP060101835 A AR P060101835A AR P060101835 A ARP060101835 A AR P060101835A AR 055939 A1 AR055939 A1 AR 055939A1
Authority
AR
Argentina
Prior art keywords
methods
eslicarbazepina
acetato
pharmaceutical compositions
prepare pharmaceutical
Prior art date
Application number
ARP060101835A
Other languages
English (en)
Inventor
Almeida Jose Luis De
Silva Patricio Manue Soares-Da
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37394802&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2005/002357 external-priority patent/WO2006120501A1/en
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of AR055939A1 publication Critical patent/AR055939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Tratamiento de diversas enfermedades y condiciones con acetato de eslicarbazepina. Uso de acetato de eslicarbazepina en un método para disminuir o reducir las crisis epilépticas en un paciente. Método para elaborar una composicion farmacéutica que comprende acetato de eslicarbazepina.
ARP060101835A 2005-05-06 2006-05-05 Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso AR055939A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2005/002357 WO2006120501A1 (en) 2005-05-06 2005-05-06 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US11/123,205 US20060252745A1 (en) 2005-05-06 2005-05-06 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Publications (1)

Publication Number Publication Date
AR055939A1 true AR055939A1 (es) 2007-09-12

Family

ID=37394802

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101835A AR055939A1 (es) 2005-05-06 2006-05-05 Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso

Country Status (2)

Country Link
US (10) US20060252745A1 (es)
AR (1) AR055939A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
UA106384C2 (ru) 2009-07-27 2014-08-26 БИАЛ-ПОРТЕЛА энд КА., С.А. ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ 5H-ДИБЕНЗ/б,ф/АЗЕПИН-5-КАРБОКСАМИДА ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ
MX2012002831A (es) * 2009-09-10 2012-05-08 Bial Portela & Ca Sa Formulaciones para suspension oral de acetato de esclicarbazepina.
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2016064711A1 (en) * 2014-10-20 2016-04-28 Anavex Life Sciences Corp. A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
CH505101A (de) 1969-03-31 1971-03-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US3637661A (en) * 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
CH605791A5 (es) * 1974-09-27 1978-10-13 Ciba Geigy Ag
EP0011603A1 (de) * 1978-11-10 1980-05-28 Ciba-Geigy Ag 10-Cyan-5H-dibenz(b,f)azepin-5-carboxamid, Verfahren zu seiner Herstellung und pharmazeutische Präparate, welche diese Verbindung enthalten
FI75561C (fi) * 1979-10-30 1988-07-11 Ciba Geigy Ag Foerfarande foer framstaellning av 5- karbamoyl-10-oxo-10,11-dihydro-5h-dibens/b,f/azepin och daertill noedvaendiga mellanprodukter.
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
JPH02502546A (ja) 1987-12-22 1990-08-16 ファーカニー、ジョン　ダブリュ 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤
EP0435826A1 (de) 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
RU2079304C1 (ru) 1990-11-08 1997-05-20 Фудзисава Фармасьютикал Ко., Лтд. Фармацевтическая композиция, обладающая иммуносупрессорной и антимикробной активностями
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
IT1261808B (it) 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
CA2575042A1 (en) 1994-04-28 1995-11-09 Alza Corporation Effective dosage form for antiepileptic drugs
US5466683A (en) * 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1283594B1 (it) 1996-04-12 1998-04-22 Trifarma Srl Derivati della 5h-dibenz- (b,f)-azepin-5-carbossiammide, loro preparazione e uso come sostanze ad azione medicinale
WO1998017692A1 (en) 1996-10-19 1998-04-30 University Of Wales, Bangor Preparation of chemically reactive polysaccharides
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
CN100379407C (zh) 1997-12-19 2008-04-09 史密丝克莱恩比彻姆公司 生产咀嚼分散片的方法
IL125244A (en) 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
AU2384500A (en) 1998-12-23 2000-07-12 Cytoscan Sciences L.L.C. Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
EP1175209A2 (en) 1999-04-30 2002-01-30 Merab Lomia Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
JP2003502296A (ja) 1999-06-15 2003-01-21 ロディア・シミ スルホニルアミド及びカルボキサミド並びに不斉触媒作用におけるそれらの使用
US20020147197A1 (en) 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
JP4249415B2 (ja) 1999-12-01 2009-04-02 ユセベ，ソシエテ アノニム Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6653294B2 (en) * 2000-02-29 2003-11-25 Food Industry Research & Development Institute Use of chitinous materials for inhibiting cellular nitric oxide production
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
WO2002005799A2 (en) 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
RU2178298C1 (ru) 2000-12-20 2002-01-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева Способ лечения больных с резистентными к фармакотерапии формами эпилепсии
IN190699B (es) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
GB0111566D0 (en) 2001-05-11 2001-07-04 Portela & Ca Sa Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide
EP1395247A2 (en) 2001-05-18 2004-03-10 Ranbaxy Laboratories, Ltd. Oxcarbazepine dosage forms
GB0112812D0 (en) * 2001-05-25 2001-07-18 Portela & Ca Sa Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom
GB0113663D0 (en) 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
RU2236224C2 (ru) 2001-10-16 2004-09-20 Российский научно-исследовательский нейрохирургический институт им. проф. А.Л. Поленова Способ лечения эпилепсии
MXPA04004470A (es) * 2001-11-12 2005-05-16 Novartis Ag Monohidroxicarbamazepina para utilizarse en la preparacion de un medicamento para el tratamiento de un trastorno afectivo y de la atencion y dolor neuropatico.
CN100352506C (zh) * 2002-02-26 2007-12-05 奥索-麦克尼尔药品公司 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途
WO2003075830A2 (en) 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
AU2003225813A1 (en) 2002-03-18 2003-10-08 Roger K. Cady Preemptive prophylaxis of migraine
EP1509207B1 (de) 2002-05-31 2009-04-29 Desitin Arzneimittel GmbH Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
DE10224170A1 (de) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
AU2003266965A1 (en) 2002-08-06 2004-02-25 Novartis Ag Use of carboxamides for the treatment of tinnitus
US20040038874A1 (en) 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
GB0221956D0 (en) 2002-09-20 2002-10-30 Novartis Ag Organic compounds
GB0223224D0 (en) 2002-10-07 2002-11-13 Novartis Ag Organic compounds
CA2497780A1 (en) 2002-10-17 2004-04-29 Novartis Ag Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7259153B2 (en) 2003-02-03 2007-08-21 Supernus Pharmaceuticals Drug formulation and delivery using crystalline methylated cyclodextrins
CA2514649A1 (en) 2003-02-17 2004-08-26 Novartis Ag Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
GB0303615D0 (en) 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
TW200501962A (en) 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
TW200502222A (en) 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
GB0307860D0 (en) 2003-04-04 2003-05-14 Novartis Ag Organic compounds
GB2401605A (en) 2003-05-12 2004-11-17 Portela & Ca Sa Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004103348A2 (en) 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
KR100546188B1 (ko) * 2003-05-24 2006-01-24 주식회사 하이닉스반도체 감지증폭수단을 포함하는 반도체 메모리 장치 및 그의감지증폭수단을 오버드라이브 하는 방법
AU2004268633B2 (en) 2003-08-29 2010-11-18 Allergan, Inc. Using selective antagonists of persistent sodium current to treat neurological disorders and pain
BRPI0414112A (pt) 2003-09-03 2006-10-31 Novartis Ag uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
JP2007522248A (ja) 2004-02-13 2007-08-09 ニューロモレキュラー・インコーポレイテッド てんかんおよび他のｃｎｓ障害の処置のための、ｎｍｄａレセプターアンタゴニストと抗てんかん薬との組み合わせ
PE20060124A1 (es) 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
AR048318A1 (es) 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
EP2384755A1 (en) 2005-05-06 2011-11-09 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB0603008D0 (en) 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
UA106384C2 (ru) 2009-07-27 2014-08-26 БИАЛ-ПОРТЕЛА энд КА., С.А. ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ 5H-ДИБЕНЗ/б,ф/АЗЕПИН-5-КАРБОКСАМИДА ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ
JP6133786B2 (ja) 2010-12-31 2017-05-24 ビアル−ポルテラ エ コンパニア，ソシエダッド アノニマ エスリカルバゼピンアセテート含有顆粒
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine

Also Published As

Publication number Publication date
US20170143736A1 (en) 2017-05-25
US20060252746A1 (en) 2006-11-09
US10695354B2 (en) 2020-06-30
US20060252745A1 (en) 2006-11-09
US20140288058A1 (en) 2014-09-25
US20100222327A1 (en) 2010-09-02
US20190307765A1 (en) 2019-10-10
US11364247B2 (en) 2022-06-21
US10675287B2 (en) 2020-06-09
US20110319388A1 (en) 2011-12-29
US20190307764A1 (en) 2019-10-10
US20210154203A1 (en) 2021-05-27
US10702536B2 (en) 2020-07-07
US20230129254A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR055939A1 (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
AR047928A1 (es) Derivados de tetrahidropiridoindol
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
GT200500360A (es) Compuestos organicos
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
AU2007257423A8 (en) Purine analogs
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
BRPI0812638A2 (pt) &#34;método para diminuir a pressão em um indivíduo método para reduzir inflamação vascular em um indivíduo, composição farmacêutica para diminuira pressão sanguínea em um indivíduo e uso de uma composição&#34;
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ATE492271T1 (de) Verfahren zur herstellung eines hydroxystilben- haltigen drogenextraktes
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina

Legal Events

Date Code Title Description
FC Refusal